

Adherium Profile

Summary

Adherium Limited (ASX: ADR) is a global leader in digital health technologies for chronic respiratory conditions including COPD and asthma. Adherium's *SmartInhaler* platform comprises wireless sensors, mobile health apps and cloud software for use with blockbuster respiratory pharmaceutical therapies.

Adherium Fast Facts

- Founded in 2001
- Total of 50 permanent staff
- Multiple FDA 510(k)s and CE Marks
- ASX listed

Board of Directors

- **Tom Lynch** - Chairman
- **Garth Sutherland** - Founder and Group CEO
- **Jeremy Curnock Cook** - Non-Executive Director
- **John Mills** - Independent Non-Executive Director
- **Bruce McHarrie** - Independent Non-Executive Director
- **Bryan Mogridge** - Independent Non-Executive Director

Senior Management

- **Garth Sutherland** - Founder and Group CEO
- **Rob Turnbull** - Chief Financial Officer
- **Ross Bradding** - Chief Operating Officer
- **Julia Chambers** - Head of Corporate Development

Markets

SmartInhaler is targeted for use in COPD and asthma applications. There is no cure for COPD and asthma, only ongoing management of these conditions.

The World Health Organisation (WHO) estimates more than 235 million people suffer from asthma and 64 million people from COPD worldwide.^{1,2}

Between 30-70% of COPD and asthma patients are not using medications as prescribed.³ Non-adherence is a common issue and results lower productivity and increased hospitalization, morbidity, and treatment costs.

Key markets include: North America, Europe and Asia Pacific.

SmartInhaler has been used in more than 65 projects and has patients in over 31 countries worldwide.

SmartInhaler Products



Wireless Sensors:

SmartTurbo, SmartTouch, SmartTouch AV, SmartDisk, SmartTrack, SmartMat, SmartFlow, SmartHandy

Communication Devices:

SmartHub, SmartKey

Mobile Apps:

SmartInhaler Apps, SmartChat Library for iOS and Android

Cloud Software:

SmartInhalerLive.com


Intellectual Property

Adherium has a number of patents granted and pending.

SmartInhaler Benefits

- Increase medication adherence by 180%, this associated with a 67% reduction in asthma morbidity score and reduce rescue medication use by 45.4% in children with asthma.⁴
- Increase medication adherence by 58.7%, and reduce the risk of severe exacerbations by 60.7% in adults with asthma.⁵
- Real-time, remote monitoring of patient medication use,
- Automatic medication reminders,
- Devices easily fit a wide range of inhalers.

SmartInhaler Platform



¹ [WHO] World Health Organization Fact Sheet No.307 Nov 2013 www.who.int

² [WHO] World Health Organization Fact Sheet No.315 Oct 2013 www.who.int

³ [WHO] World Health Organization. Adherence to long term therapies, time for action. Geneva: World Health Organization; 2003, accessed 2013 Aug 28.

⁴ Chan, Amy HY, et al. "The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial." *The Lancet Respiratory Medicine* 3.3 (2015): 210-219.

⁵ Foster, Juliet M., et al. "Inhaler reminders improve adherence with controller treatment in primary care patients with asthma." *Journal of Allergy and Clinical Immunology* 134.6 (2014): 1260-1268.